The Food and Drug Administration today approved a naloxone hydrochloride nasal spray to treat opioid overdoses that delivers 8 milligrams of naloxone, up from 2 mg or 4 mg in previously approved products. 
 
“Addressing the opioid crisis is a top priority for the FDA, and we will continue our efforts to increase access to naloxone and place this important medicine in the hands of those who need it most,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research. 
 

Related News Articles

Headline
A report from AARP and the National Alliance for Caregiving released today found nearly 1 in 4 U.S. adults (63 million) are caring for an adult or child…
Headline
The Departments of Justice and Health and Human Services today announced the creation of the DOJ-HHS False Claims Act Working Group to combat health care fraud…
Headline
The Centers for Medicare & Medicaid Services today announced it has identified a fraud scheme targeting Medicare providers and suppliers. CMS said scammers…
Headline
The Trump administration yesterday released executive orders on reducing anti-competitive regulatory barriers and repealing certain regulations deemed unlawful…
Headline
The Department of Health and Human Services Feb. 28 announced that it is rescinding its Nixon-era policy on inviting public participation when making rules and…
Headline
The Food and Drug Administration yesterday released recommendations for streamlining the approval process for medical devices that use artificial intelligence…